Immunotherapy effects of apatinib mesylate combined with toripalimab on triple-negative breast cancer mice

Immunotherapy effects of apatinib mesylate combined with toripalimab on triple-negative breast cancer mice

Objective To investigate the application and effects of apatinib mesylate combined with programmed death receptor-1 (PD-1) monoclonal antibody (mAb)—toripalimab in immunotherapy for triple negative breast cancer (TNBC). Methods Among 40 female BALB/C mice, 8 mice were randomly selected as the blank...

Full description

Bibliographic Details
Main Authors: DING Xiaoyun, CAO Di, MA Xiaoxia, HU Zhiqiang
Format: Article
Language:zho
Published: The Editorial Department of Chinese Journal of Clinical Research 2024-03-01
Series:Zhongguo linchuang yanjiu
Subjects:
apatinib mesylate
anti-programmed death receptor
monoclonal antibody
toripalimab
triple-negative breast cancer
tumor inhibition rate
apoptosis
metastasis
myeloid-derived suppressor cell
tumor-associated macrophages
regulatory t cell
Online Access:http://zglcyj.ijournals.cn/zglcyj/ch/reader/view_abstract.aspx?file_no=20240305

Internet

http://zglcyj.ijournals.cn/zglcyj/ch/reader/view_abstract.aspx?file_no=20240305

Similar Items